We hypothesized that in-utero SSRI exposure affects Apgar scores and immediate post-delivery oxygen requirements.
STUDY DESIGN:
SSRI in-utero exposure was assessed retrospectively in preterm neonates ≥ 28 weeks gestation and term neonates. Primary outcome was Apgar <7 at five minutes and delivery room oxygen requirements. Secondary endpoints included one-minute Apgar, length of stay, birth weight, and NICU admission.
RESULTS:
Fifty-one preterm and 117 term neonates were exposed to a SSRI; mostly to sertraline. Pre-term SSRI-exposed neonates had 4.1 times higher delivery room oxygen requirements. One minute Apgar <7 was 3.5 times higher and NICU admission 5 times higher 95% CI (1.3–19) in SSRI-exposed term neonates. Higher doses of sertraline had associated adverse outcomes.
CONCLUSION:
In-utero SSRI exposure was associated with increased neonatal care at birth, differences in Apgar scores compared with controls, and increased NICU admissions. Higher sertraline doses were associated with poorer outcomes.
ZoegaH, KielerH, NørgaardM, et al. Use of SSRI and SNRI Antidepressants during pregnancy: A population-based study from Denmark, Iceland, Norway and Sweden. PLoS One2015;10(112):e0144474.
MelvilleJL, GavinA, GuoY, FanMY, KatonWJ. Depressive disorders during pregnancy: Prevalence and risk factors in a large urban sample. Obstet Gynecol2010;16(5):1064–70.
4.
KoJY, FarrSL, DietzPM, RobbinsCL. Depression and Treatment Among U.S. Pregnant and Non-pregnant Women of Reproductive Age, 2005–2009. J Women Health2012;21(8):830–6.
5.
AndradeSE, RaebelMA, BrownJ, et al. Use of antidepressant medications during pregnancy: A multisite study. Am J Obstet Gynecol2008;198:194e1–194e5.
6.
SieSD, WenninkJM, van DrielJJ, et al. Maternal use of SSRIs, SNRI’s, and NaSSAs: Practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed2012;97(6):F472–6.
7.
Citalopram package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2012.
8.
Escitalopram package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2012.
9.
Fluoxetine package insert. Indianapolis, IN: Eli Lilly and Company; 2011.
10.
Fluvoxamine package insert. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2012.
11.
Paroxetine package insert. Research Triangle Park, NC: GlaxoSmithKline; 2011.
12.
Sertraline package insert. New York, NY: Pfizer; 2012.
WisnerKL, SitDK, HanusaBH, et al. Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. Am J Psychiatry2009;166:557–66.
15.
YonkersKA, WisnerKL, StewartDE, et al. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry2009;31(5):403–13.
16.
GrzeskowiakLE, GilbertAL, MorrisonJL. Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy. Drug Saf2011;34(11):1027–48.
17.
SalisburyAL, WisnerKL, PearlsteinT, BattleCL, StroudL, LesterBM. Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety2011;28:1008–19.
18.
ChambersCD, JohnsonKA, DickLM, FelixRJ, JonesKL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med1996;335:1010–15.
19.
FerreiraE, CarcellerAM, AgogueC, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics2007;119:52–9.
20.
MulderEJH, VerversFFT, de HuesR, VisserGHA. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacol2011;36:1961–71.
21.
ChambersCD, Hernandez-DiazS, Van MarterLJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med2006;354:579–87.
22.
MohanCG, MooreJJ. Clinical perinatal/neonatal case presentation – Fluoxetine toxicity in a preterm infant. J Perinatol2000;20:445–46.
23.
LundNN, PedersenLH, HenriksenTB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med2009;163(10):949–54.
24.
CasperRC, FleisherBE, Lee-AncajasJC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr2003;142:402–8.
25.
NordengH, van GelderMMHJ, SpigsetO, KorenG, EinarsonA, Eberhard-GranM. Pregnancy outcome after exposure to antidepressants and the role of maternal depression. J Clin Psychopharmacol2012;32:186–94.
26.
FaulF. G*Power software version 3.0.8 University at Kiel, Germany.
27.
KennedyD. Choosing an SSRI in pregnancy: Clinical context versus statistical significance. Australian & New Zeland Journal of Psychiatry2013;47(12):1101–3.
28.
NagaiM, OhtaniH, SatohH, MatsuokaS, HoriS, FujiiT. Characterization of transplacental transfer of paroxetine in perfused human placenta: Development of a pharmacokinetic model to evaluate tapered dosing. Drug Met Dispos2013;41:2124–32.
29.
CasperRC, FleisherBE, Lee-AncajasJC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatric2003;142:402–8.
30.
LattimoreKA, DonnSM, KcirotiN, KemperAR, NealCR, VazquezDM. Selective serotonin reuptake inhibitor use during pregnancy and effects on the fetus and newborn: A metanalysis. J Peritnatol2005;25:595–604.
31.
KallenB. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med2004;158:312–6.
32.
CosteiAM, KozerE, HoT, ItoS, KorenG. Perinatal outcome following third trimester exposure to paroxetine. Arch Adolescent Medicine2002;156:1129–32.
33.
ZeskindPS, StephensLE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics2004;113:368–75.
34.
LaineK, HeikkinenT, EkbladU, KeroP. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry2003;60:720–6.
35.
Levinson CastielR, MerlobP, LinderN, SirotaL, KlingerG. Neonatal abstinence syndrome after in-utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med2006;160:173–6.
36.
BoucherN, BairamA, Beaulac-BaillargeonL. A new look at neonates clinical presentation after in-utero exposure to antidepressants in late pregnancy. J Clin Psychpharmacol2008;28:334–9.
37.
MaschiS, Clavenna CampiR, SchiavettiB, BernatM, BonatiM. Neonatal outcome following pregnancy exposure to antidepressants: A prospective controlled cohort study. BJOG2008;115:283–9.
38.
BeckmanDA. Mechanisms of teratogenesis. Ann Rev Pharmacol Toxicol1984;24:483–500.
39.
BerardA, RamosE, ReyE, BlaisL, St AndreM, OraichiD. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage: Birth Defects Research part B. Dev Reprod Toxicol2007;8018–27.
40.
RocaA, Garcia EsteveL, ImazML, et al. Obstetrical and neonatal outcomes after prenatal exposure to serotonin selective inhibitors. The relevance of dose. J Affect Disorde2011;135:208–15.
41.
CasperRC, GilesAA, FleisherBE, BaranJ, EnnsG, LazzeroniLC. Length of prenatal exposure to selective serotonin reuptake inhibitor antidepressants: Effects on neonatal adaptation and psychomotor development. Psychopharmacol2011;217:211–219.
42.
HendrickV, SmithLM, SuriR, HwandS, HaynesD, AltshulerL. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol2003;188:812–15.
